Invited Speakers
Marion Peters
2025 William H. Prusoff HEP DART Lifetime Achievement Award Recipient
University of California, San Francisco, USA
Academic Speakers
Homie Razavi
Centers for Disease Analysis Foundation, USA
"Plenary Lecture: Progress towards Hepatitis B and C Elimination"
Natasha Martin
UC San Diego, USA
"Economic impact and elimination strategies for HCV and HBV"
Miriam Levy
Liverpool Hospital and UNSW, Australia
"Hepatitis elimination is not achievable without a SEARCH"
Pietro Lampertico
University of Milan, Italy
"The HDV epidemic – is the problem bigger or smaller than we think and will this affect the treatment landscape? "
Manal
El-Sayed
Aims Sans University, Egypt
"Plenary Lecture: status of Obesity and MASLD in Africa and America"
Tatyana Kushner
Weill Cornell Medicine, USA
"Updates in Guidance and Approach to HBV and HCV in pregnant people - critical population for our Path To HBV/HCV Elimination"
Laura Malone
World Hepatitis Alliance, Switzerland
"Impact and importance of involving people with lived experience and community groups in drug development processes"
Barbara Testoni
Lyons University, France
"Plenary Lecture:Basic research for Hepatitis B infections"
Mark Sulkowski
Johns Hopkins University, USA
"Novel antivirals for HBV functional cure"
Yuen Man-Fung
Hong Kong University, Hong Kong
"Special Lecture: Novel biomarkers in HBV cure, and endpoints"
Charles Flexner
Johns Hopkins University, USA
"Plenary Lecture: Long-acting injectables for HBV & HCV: a key to elimination"
Jordan Feld
University of Toronto, Canada
"Using CHIM (Controlled Human Infection Model) to accelerate HCV vaccine development"
Andrea Cox
Johns Hopkins University, USA
"HBV vaccines in people living with HIV and current HCV vaccine efforts"
Laurence Sperling
Emory University, USA
"Plenary Lecture:MASLD and cardiovascular disease"
Veronica Miller
University of California Berkeley, USA
"Reasonably likely surrogate endpoint for MASH - road to validation"
Arun Sanyal
Virginia Commonwealth University, USA
"GLP-1s and combination— the impact of these drugs cannot be understated and will influence future drug development for MASLD/MASH"
Stanley Lemon
University of North Carolina Chapel Hill, USA
"Cellular host factors required for hepatitis A virus infection"
Michael Manns
Hannover Medical School, Germany
"Primary sclerosing cholangitis – the black box of hepatology with multiple therapeutic strategies under development"
Tarik Asselah
Hospital Beaujon, France
"Emerging therapies for Hepatitis D and long-term outcomes of antiviral treatment in chronic viral hepatitis"
George Lau
Humanity and Health Medical Center, Hong Kong, China
"Plenary Lecture: Systemic therapy for HCC-Asian perspective"
Richard Finn
University of California Los Angeles, USA
"HCC: the path to molecular targeting: HCC is a "drugable" cancer "
Adam Gehring
UHN Toronto, Canada
"Curing HBV by safely modifying the immune system"
Fabian Zoulim
Lyon University, France
"Plenary Lecture: Gene editing and epigenetic modification for HBV cure"